# Non-coding RNAs: Emerging contributors to chemoresistance in chronic myeloid leukemia

## TL;DR

Non-coding RNAs are emerging as key players in chemoresistance in chronic myeloid leukemia, offering new therapeutic opportunities.

## Contribution

The paper reviews non-coding RNAs involved in chemoresistance in CML and highlights their potential as therapeutic targets.

## Key findings

- Non-coding RNAs significantly contribute to chemoresistance in CML cells.
- Understanding these RNAs could lead to new treatment strategies for resistant CML.
- Non-coding RNAs may serve as valuable therapeutic targets in CML.

## Abstract

Chronic myeloid leukemia (CML), is a myeloproliferative disease characterized by unregulated growth of blood forming cells in bone marrow and blood. The t(9;22)(q34;q11.2) translocation, which results in the formation of a hyperactive tyrosine kinase (BCR-ABL), is a hallmark of this disorder. Tyrosine kinase inhibitors such as imatinib has shown a great promise in reduction of CML cells. However, development of resistance to tyrosine kinase inhibitors has raised a great clinical concern about their future applications. Recently, non-coding RNAs, have shown to play significant regulatory roles in development of chemoresistance in CML cells. Discovering the underlying mechanisms of these non-coding RNAs might provide new opportunities for treating chemo-resistant forms of CML. These non-coding RNAs could be considered valuable therapeutic targets if they are found to play a role in the development of chemoresistance in CML cells. We mentioned the identified non-coding RNAs in development of chemoresistance in CML cells.